Format

Send to

Choose Destination
J Biomed Sci. 2017 Jul 11;24(1):43. doi: 10.1186/s12929-017-0349-5.

V-J combinations of T-cell receptor predict responses to erythropoietin in end-stage renal disease patients.

Wong HS1,2, Chang CM3, Kao CC4,5, Hsu YW6, Liu X7, Chang WC8, Wu MS9,10, Chang WC11,12,13,14,15.

Author information

1
Department of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, No. 250, Wuxing St, Xinyi District, Taipei City, 11031, Taiwan.
2
Master's Program for Clinical Pharmacogenomics and Pharmacoproteomics, School of Pharmacy, Taipei Medical University, No. 250, Wuxing St, Xinyi District, Taipei City, 11031, Taiwan.
3
Ph.D. Program for Biotechnology in Medicine, College of Medical Science and Technology, Taipei Medical University, No. 250, Wuxing St, Xinyi District, Taipei City, 11031, Taiwan.
4
Division of Nephrology, Department of Internal Medicine, Shuang Ho Hospital, No. 291, Zhongzheng Road, Zhonghe District, New Taipei City, 235, Taiwan.
5
Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, No. 250, Wuxing St, Xinyi District, Taipei City, 11031, Taiwan.
6
The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, No. 250, Wuxing St, Xinyi District, Taipei City, 11031, Taiwan.
7
Section of Hematology/Oncology, Department of Medicine, The University of Chicago, 5801 S Ellis Ave, Chicago, IL, 60637, USA.
8
Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, No. 250, Wuxing St, Xinyi District, Taipei City, 11031, Taiwan.
9
Division of Nephrology, Department of Internal Medicine, Shuang Ho Hospital, No. 291, Zhongzheng Road, Zhonghe District, New Taipei City, 235, Taiwan. maiszuwu@tmu.edu.tw.
10
Department of Internal Medicine, School of Medicine, Taipei Medical University, No. 250, Wuxing St, Xinyi District, Taipei City, 11031, Taiwan. maiszuwu@tmu.edu.tw.
11
Department of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, No. 250, Wuxing St, Xinyi District, Taipei City, 11031, Taiwan. wcc@tmu.edu.tw.
12
Master's Program for Clinical Pharmacogenomics and Pharmacoproteomics, School of Pharmacy, Taipei Medical University, No. 250, Wuxing St, Xinyi District, Taipei City, 11031, Taiwan. wcc@tmu.edu.tw.
13
Cancer Center, Kaohsiung Medical University Hospital, No. 100, Ziyou 1st Road, Sanmin District, Kaohsiung City, 807, Taiwan. wcc@tmu.edu.tw.
14
Department of Pharmacy, Wan Fang Hospital, Taipei Medical University, No. 111, Section 3, Xinglong Road, Wenshan District, Taipei City, 116, Taiwan. wcc@tmu.edu.tw.
15
Center for Biomarkers and Biotech Drugs, Kaohsiung Medical University, No. 100, Shiquan 1st Road, Sanmin District, Kaohsiung City, 807, Taiwan. wcc@tmu.edu.tw.

Abstract

BACKGROUND:

Anemia is common among end-stage renal disease (ESRD) patients who undergone hemodialysis. The total reduction of red blood cell (RBC) count is associated with poor prognosis in these patients. Although erythropoietin (EPO) has been used as an effective treatment for ESRD patients with anemia, a large number of patients still present poor responses to EPO treatment.

METHODS:

We measured T-cell receptor sequencing profiles, including length of complementarity-deteremining region 3 (CDR3), intra- and inter-group (EPO resistant vs. responsive) clonotype diversity, V(D)J usage profiles and V-J combinations from ESRD patients and to investigate the correlation between these features and EPO treatment efficacy.

RESULTS:

Our results revealed statistical significance in the top 3 ~ 15 most abundant joint distributions of Vβ/Jβ among the two groups, suggesting the importance of V or J gene utilization in the EPO response of ESRD patients.

CONCLUSIONS:

In summary, we provided evidence addressing the potential correlation between the immune repertoire and EPO response in ESRD patients.

TRIAL REGISTRATION:

TMU-JIRB 201309026. Registered 16 October 2013.

KEYWORDS:

End-stage renal disease; Erythropoietin treatment; High-throughput sequencing; T-cell receptor repertoire

PMID:
28697735
PMCID:
PMC5504791
DOI:
10.1186/s12929-017-0349-5
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center